WO1994004680A9 - Interleukine-13 humaine - Google Patents

Interleukine-13 humaine

Info

Publication number
WO1994004680A9
WO1994004680A9 PCT/US1993/007645 US9307645W WO9404680A9 WO 1994004680 A9 WO1994004680 A9 WO 1994004680A9 US 9307645 W US9307645 W US 9307645W WO 9404680 A9 WO9404680 A9 WO 9404680A9
Authority
WO
WIPO (PCT)
Prior art keywords
cells
human
cell
expression
hil
Prior art date
Application number
PCT/US1993/007645
Other languages
English (en)
Other versions
WO1994004680A1 (fr
Filing date
Publication date
Priority claimed from US08/012,543 external-priority patent/US5596072A/en
Application filed filed Critical
Priority to AU50107/93A priority Critical patent/AU5010793A/en
Priority to EP93920049A priority patent/EP0656947A1/fr
Priority to JP6506436A priority patent/JPH07508179A/ja
Publication of WO1994004680A1 publication Critical patent/WO1994004680A1/fr
Publication of WO1994004680A9 publication Critical patent/WO1994004680A9/fr

Links

Abstract

On décrit des acides nucléiques codant l'IL-13 humaine, ainsi que des protéines purifiées d'IL-13 et des fragments de ces dernières. On décrit aussi des anticorps tant polyclonaux que monoclonaux. On décrit enfin des procédés permettant d'utiliser de telles compositions à des fins diagnostiques et thérapeutiques.
PCT/US1993/007645 1992-08-21 1993-08-18 Interleukine-13 humaine WO1994004680A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU50107/93A AU5010793A (en) 1992-08-21 1993-08-18 Human interleukin-13
EP93920049A EP0656947A1 (fr) 1992-08-21 1993-08-18 Interleukine-13 humaine
JP6506436A JPH07508179A (ja) 1992-08-21 1993-08-18 ヒトインターロイキン−１３

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US93341692A 1992-08-21 1992-08-21
US07/933,416 1992-08-21
US1097793A 1993-01-29 1993-01-29
US08/010,977 1993-01-29
US08/012,543 1993-02-01
US08/012,543 US5596072A (en) 1992-08-21 1993-02-01 Method of refolding human IL-13

Publications (2)

Publication Number Publication Date
WO1994004680A1 WO1994004680A1 (fr) 1994-03-03
WO1994004680A9 true WO1994004680A9 (fr) 1994-05-11

Family

ID=27359336

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/007645 WO1994004680A1 (fr) 1992-08-21 1993-08-18 Interleukine-13 humaine

Country Status (6)

Country Link
EP (1) EP0656947A1 (fr)
JP (1) JPH07508179A (fr)
AU (1) AU5010793A (fr)
CA (1) CA2142860A1 (fr)
IL (1) IL106732A0 (fr)
WO (1) WO1994004680A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE381624T1 (de) 1994-05-09 2008-01-15 Oxford Biomedica Ltd Retrovirale vektoren mit verminderter rekombinationsrate
US6428788B1 (en) 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
US6518061B1 (en) 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5830453A (en) * 1995-05-19 1998-11-03 Emory University Use of IL-13 to induce 15-lipoxygenase
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US7078494B1 (en) 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
WO1998010638A1 (fr) * 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Molecules d'interet therapeutique
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
WO1999006059A2 (fr) * 1997-07-30 1999-02-11 Board Of Regents, The University Of Texas System Procedes et compositions relatifs a la cytotoxicite induite par l'oxyde nitrique
US6171856B1 (en) 1997-07-30 2001-01-09 Board Of Regents, The University Of Texas System Methods and compositions relating to no-mediated cytotoxicity
US6471957B1 (en) 1998-05-29 2002-10-29 Heska Corporation Canine IL-4 immunoregulatory proteins and uses thereof
US6482403B1 (en) * 1998-05-29 2002-11-19 Heska Corporation Caniney IL-13 immunoregulatory proteins and uses thereof
USRE40374E1 (en) 1998-05-29 2008-06-10 Heska Corporation Canine IL-13 immunoregulatory proteins and uses thereof
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
AU780031B2 (en) * 1998-12-14 2005-02-24 Genetics Institute, Llc Cytokine receptor chain
DK1151300T3 (da) * 1998-12-23 2010-07-12 Medsaic Pty Ltd Assay til påvisning af en bindingspartner
GB0004016D0 (en) * 2000-02-22 2000-04-12 Royal Brompton Hospital Biological material and uses thereof
WO2002055100A2 (fr) * 2000-10-20 2002-07-18 Genetics Institute, Llc Procédé et composition pour renforcer une réponse immunitaire
IL159215A0 (en) * 2001-06-07 2004-06-01 Wyeth Corp A solution of interleukin-13 and methods utilizing the same
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
EP1587534A1 (fr) * 2003-01-17 2005-10-26 Children's Hospital Medical Center Traitement des allergies a base de tff2 ou d'un agent l'induisant
KR101073590B1 (ko) * 2003-07-15 2011-10-14 메디뮨 리미티드 Ｉｌ-13에 대한 인간 항체 분자
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
SG10201900535UA (en) 2003-12-23 2019-02-27 Genentech Inc Novel anti-il 13 antibodies and uses thereof
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
CA2587903A1 (fr) 2004-11-17 2006-05-26 Amgen Fremont Inc. Anticorps monoclonaux entierement humains diriges contre l'il-13
EP2532678A1 (fr) 2005-10-21 2012-12-12 Novartis AG Anticorps humains dirigés contre l'IL-13 et utilisations thérapeutiques
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
UA115964C2 (uk) 2006-09-08 2018-01-25 Еббві Айрленд Анлімітед Компані Інтерлейкін-13-зв'язувальний білок
BR112013013460A8 (pt) 2010-12-16 2019-02-12 Genentech Inc métodos de identificação de um paciente com asma, método de monitoramento de um paciente com asma, uso de um kit de detecção de periostina total, kit de medição da periostina total, uso de um anticorpo anti-il-13, uso de uma quantidade terapeuticamente eficaz de lebrikizumab, uso de um inibidor da via de th2, método de avaliação de eventos adversos, anticorpo anti-periostina e teste de periostina total
EP2850093B1 (fr) 2012-01-27 2019-01-09 The Board of Trustees of the Leland Stanford Junior University Polypeptides d'il-13 thérapeutiques
WO2015038888A1 (fr) 2013-09-13 2015-03-19 Genentech, Inc. Procédés et compositions comprenant des polypeptides recombinants purifiés
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
CA2925417C (fr) 2013-09-24 2023-10-24 Fahar Merchant Proteines de fusion se liant au recepteur de l'interleukine 4 et utilisations associees
WO2020212602A1 (fr) 2019-04-19 2020-10-22 Synerkine Pharma B.V. Formation en réseaux de récepteurs de cytokines à visée thérapeutique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0506574T3 (da) * 1991-03-29 1996-04-09 Sanofi Sa Protein med aktivitet af cytokintype, rekombinant-DNA, der koder for dette protein, celler og transformerede mikroorganismer

Similar Documents

Publication Publication Date Title
US5596072A (en) Method of refolding human IL-13
WO1994004680A9 (fr) Interleukine-13 humaine
EP0656947A1 (fr) Interleukine-13 humaine
US6423500B1 (en) Mammalian receptors for interleukin-10
Kishimoto et al. Molecular regulation of B lymphocyte response
EP1349873B1 (fr) Modulation de reactions de cellules t induites par il-15 et il-2
Oppmann et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12
Grabstein et al. Purification to homogeneity of B cell stimulating factor. A molecule that stimulates proliferation of multiple lymphokine-dependent cell lines.
Zurawski et al. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells
US6001973A (en) Antagonists of interleukin-15
EP1899364B1 (fr) Compositions et methodes d'immunomodulation d'un organisme
US5457038A (en) Natural killer stimulatory factor
US6797263B2 (en) Compositions and methods for achieving immune suppression
AU681178B2 (en) Agonists and antagonists of human interleukin-10
HU208710B (en) Method for preparation of mammalian human il-4, dna encoding il-4, host cell and pharmaceutical composition comprising human il-4
AU2001261585A1 (en) Compositions and methods for achieving immune suppression
WO2003087320A2 (fr) Antagonistes de il-21 et modulation des reponses des lymphocytes t induites par il-21
EP1392830B1 (fr) Production et utilisation de mutants d'interleukine-18
US7078506B2 (en) Canineil-4nucleic acid molecules and uses thereof
McKenzie et al. Interleukin-13: characterization and biologic properties
CA2234045A1 (fr) Agonistes du recepteur de l'il-3
AU2006246489A1 (en) Compositions and methods for achieving immune suppression